CELLvo™Matrix Plus

Predictive cardiotoxicity assays explained

VIDEO: Predictive cardiotoxicity assays explained

Drs. Herron and Block discuss hiPSC-CM expanded on CELLvo™Matrix Plus

Todd Herron, Ph.D., of the University of Michigan and a founder of Cartox, and Travis Block, Ph.D., the Chief Technology Officer of StemBioSys, discuss their collaborative research in a video. Dr. Herron briefly described the experiment and some of the benefits that were discovered for the pharmaceutical industry, including successful maturation of hiPSC-CMs and the subsequent ability for predictively testing cardiac safety of drugs in the early development stage.